ProPhase Labs (PRPH) Misses Q3 EPS by 33c; Reports Cash and Cash Equivalents of $22.9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures gain as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2021
November 12, 2021 8:30 AM ESTCompany to hold a conference call November 12, 2021 at 11:00AM ET
Garden City, NY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today reported its financial and operational results for the three months ended September 30, 2021.
Financial highlights for the quarter ended September 30, 2021 include the following:
Total revenue of $9.5... More


